. 2021 Feb 5;28(11):1161–1174. doi: 10.5551/jat.60152

Supplementary Table 1. Baseline and follow-up lipid markers.

Variable	RP group n = 29			Non-RP group n = 113
Variable	Baseline	Follow-up	p value (vs. baseline)	Baseline	Follow-up	p value (vs. baseline)
TG, mg/dL	114 (76 - 160.5)	138 (96 - 192.5) ^＊	0.26	109 (55.5 - 162.5)	99 (71 - 145)	0.36
Change in TG , mg/dL		19 (-15 - 57) ^＊			-9 (-51.5 - 21.5)
Percent of change in TG, %		25.0 (-12.4 - 50.9) ^＊			-9.7 (-31.3 - 33.6)
LDL-c, mg/dL	131.5±37.7	80.0±20.5	＜0.0001	122.6±39.0	75.5±20.0	＜0.0001
Change in LDL-c, mg/dL		-51.5±40.5			-47.1±41.4
Percent of change in LDL-c, %		-34.8±23.7			-33.2±24.9
Non-HDL-c, mg/dL	154.9±40.3	107.3±22.0	＜0.0001	146.6±41.1	99.0±21.7	＜0.0001
Change in non-HDL-c, mg/dL		-47.7±42.7			-47.5±43.6
Percent of change in non-HDL-c, %		-26.6±22.9			-28.0±22.7
Sd-LDL-c, mg/dL	37.9±13.7	26.9±9.6 ^＊	0.0008	36.6±20.5	22.4±8.9	＜0.0001
Change in sd-LDL-c, mg/dL		-11.0±15.1			-14.2±19.7
Percent of change in sd-LDL-c, %		-22.3±31.0			-26.5±35.0
Apo B, mg/dL	106.7±23.2	77.2±15.2	＜0.0001	99.4±28.5	71.5±15.6	＜0.0001
Change in Apo B, mg/dL		-28.4±26.4			-28.8±28.6
Percent of change in Apo B, %		-23.9±20.2			-24.6±22.5
Apo C3, mg/dL	9.9 (7.5 - 12.6)	10.1 (8.4 - 13.0) ^＊	0.06	8.8 (7.1 - 11)	8.7 (7.1 - 11)	0.41
Change in Apo C3, mg/dL		1.8 (-0.2 - 3.6) ^＊			-0.2 (-2.4 - 1.4)
Percent of change in Apo C3, %		18.2 (-0.8 - 45.4) ^＊			-2.2 (-21.4 - 16.6)
RL-c, mg/dL	5.8 (3.7 - 8.0)	4.3 (2.7 - 6.9) ^＊	0.12	5.0 (3.4 - 7.5)	3.1 (2.1 - 4.9)	＜0.0001
Change in RL-c, mg/dL		-1.2 (-3.3 - 0.15)			-1.6 (-3.9 - -0.1)
Percent of change in RL-c, %		-26.7 (-49.6 - -3.9)			-33.3 (-58.0 - -1.5)

Data are expressed as mean±standard deviation (SD), or median (25% and 75% quartiles). ^＊ p ＜0.05, compared with corresponding Non-RP group by unpaired t -test or Wilcoxon’s signed-rank test.